DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 227
- Registration Number
- NCT00698828
- Locations
- 🇷🇴
Spitalul Clinic de Pneumoftiziologie Constanta, Cartier Palazul Mare, Constanţa, Romania
🇦🇷Instituto de Investigaciones Clínicas Cipolletti, Cipolletti, Río Negro, Argentina
🇦🇷Clinica del Tórax, Rosario, Santa Fe, Argentina
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 207
- Registration Number
- NCT00654745
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2500
- Registration Number
- NCT00649389
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 27
- Registration Number
- NCT00623363
- Locations
- 🇺🇸
Suny Downstate Medical Center, Brooklyn, New York, United States
🇺🇸UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇬🇹Hospital Multimedica, Guatemala, Guatemala
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 25
- Registration Number
- NCT00616733
Effects of CS-8080 in Healthy Volunteers
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 72
- Registration Number
- NCT00613431
- Locations
- 🇺🇸
MDS Pharma Services, Neptune, New Jersey, United States
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 19
- Registration Number
- NCT00603941
- Locations
- 🇺🇸
Univ of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Ohio State Univ, Columbus, Ohio, United States
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 94
- Registration Number
- NCT00571519
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 502
- Registration Number
- NCT00570739
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 185
- Registration Number
- NCT00527514
© Copyright 2024. All Rights Reserved by MedPath